# CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

> **NCT03726398** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Franz Rischard, DO**

## Conditions studied

- Interstitial Lung Disease
- Scleroderma
- Pulmonary Hypertension

## Interventions

- **DRUG:** Opsumit 10 Mg Tablet

## Key facts

- **NCT ID:** NCT03726398
- **Lead sponsor:** Franz Rischard, DO
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-01
- **Primary completion:** 2020-08-03
- **Final completion:** 2020-08-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Did not identify eligible candidates
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03726398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03726398, "CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03726398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*